<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310646</url>
  </required_header>
  <id_info>
    <org_study_id>LP0053-1030</org_study_id>
    <nct_id>NCT02310646</nct_id>
  </id_info>
  <brief_title>Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris</brief_title>
  <official_title>A Clinical Trial Gathering Insight of Patient Reported Factors That Influence Preference Following Once Daily Topical Treatment With LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To gather insight on how product attributes affect usability by investigating the factors
      that are thought to influence patient preference to topical anti-psoriatic treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An international, multi-centre, prospective, open-label, randomised, 2-arm, cross-over study
      with 14-days once daily treatment in subjects with psoriasis vulgaris. To gather insight on
      how product attributes affect usability by investigating the factors that are thought to
      influence patient preference to topical anti-psoriatic treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Treatment Preference by Subject's Preference Assessment (SPA) at Week 2 and Association With Baseline Characteristics</measure>
    <time_frame>2 weeks</time_frame>
    <description>The SPA questionnaire was completed at Week 2 and consisted of 2 parts:
(i) the subject indicated if they preferred LEO 90100 foam or Daivobet® gel based on their experience using these products for 1 week each during the 2-weeks treatment period; (ii) the subject indicated how much each of the 22 items under the application, formulation, and container domains contributed to their overall decision of which product they preferred. This part of the SPA tool used a 4-point scale ranging from 'very important factor' to 'not at all important factor'.
The statistical significance of each of the following 7 baseline characteristics (gender, age, disease severity, distribution, plaque size, skin thickness, onset) was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Results of multiple regression analyses are provided in the Clinical Study Report which can be found on the LEO Pharma website.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Within Subject Difference in Response to Topical Product Usability Questionnaire (TPUQ) Items Between Trial Treatments</measure>
    <time_frame>2 weeks</time_frame>
    <description>Each response category (item 1 to 25) was assigned a numeric score (-2=strongly disagree, -1=slightly disagree, 0=neither agree nor disagree, 1=slightly agree, 2=strongly agree). For item 26, the assigned score were from -2=very dissatisfied to 2=very satisfied.
Summary scores were calculated by summing numeric scores for items under each domain, i.e., application (items 1-9; score range -18 to +18), formulation (items 10-18; score range -18 to +18), container (items 19-22; score range -8 to +8), and satisfaction (items 23-25; score range -6 to +6). Positive scores indicate agreement with domains' items.
A total TPUQ summary score (item 1-25; score range -50 to +50) was also calculated. The summary scores were analysed in the same way as the individual questions. The higher score signifies higher preference in that domain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Within Subject Difference in Response to TPUQ Between the Last Topical Anti-psoriatic Treatment and Each of the 2 Trial Treatments</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>The TPUQ tool was used to evaluate the subject's latest topical treatment at Baseline (used within 3 months prior to baseline). TPUQ assessments of trial treatments at Week 1 and Week 2.
Each response category (item 1 to 25) was assigned a numeric score from-2=strongly disagree to 2=strongly agree. For item 26 the assigned scores were from -2=very dissatisfied to 2=very satisfied.
Summary scores were calculated by summing numeric scores for items under each domain, i.e., application (items 1-9; score range -18 to +18), formulation (items 10-18; score range -18 to +18), container (items 19-22; score range -8 to +8), and satisfaction (items 23-25; score range -6 to +6).
For each subject and each item, the latest topical treatment score was compared with each study treatment by calculating the difference between the scores, i.e., by subtracting the latest topical treatment score from each study medication score. The higher score signifies higher preference in that domain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Responses to Comparison to Last Topical Treatment Questionnaire (CLTT) for Each of the Two Trial Treatments (Foam or Gel)</measure>
    <time_frame>At Week 1 and Week 2</time_frame>
    <description>Subjects in both arms (foam-gel; gel-foam) indicated whether they preferred latest topical treatment, LEO 90100 aerosol foam, Daivobet® gel, or did not have any preference.
The subjects compared the trial treatment used the previous week with the latest topical treatment (used within 3 months prior to baseline; CLTT analysis set). Each item was scored with either 'prefer latest treatment', 'no preference', or 'prefer trial medication (foam or gel)'. A subject could prefer both study treatments over the latest topical treatment. The percentage is given for the number of subjects preferring foam and number of subjects preferring gel.</description>
  </other_outcome>
  <other_outcome>
    <measure>Within Subject Difference in Response to Vehicle Preference Measure (VPM) Items Between Trial Treatments</measure>
    <time_frame>At Week 1 and Week 2</time_frame>
    <description>The VPM questionnaire was analysed the same way as the TPUQ. Numeric scores were calculated by assigning the following values to each response category: -3 = Extremely unappealing, -2 = Moderately unappealing, -1 = Slightly unappealing, 0 = Neutral, 1 = Slightly appealing, 2 = Moderately appealing, 3 = Extremely appealing. A summary score was defined as the sum of all questions and could range from -21 to 21.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reasons for Overall Preference as Assessed by Subject's Preference Assessment (SPA) at Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>Comparison of contribution of each product attribute in the stated preference between trial treatments (foam and gel)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Treatment group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 Aerosol Foam</intervention_name>
    <description>Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week</description>
    <arm_group_label>Treatment group 1</arm_group_label>
    <arm_group_label>Treatment group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivobet® gel</intervention_name>
    <description>Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.</description>
    <arm_group_label>Treatment group 1</arm_group_label>
    <arm_group_label>Treatment group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. At Day 1 (Visit 1), a clinical diagnosis of psoriasis vulgaris of at least 6 months
             duration involving the trunk and/or limbs amenable to treatment with a maximum of 60 g
             of study medication per week

          2. Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and
             skin folds) involving 2-30% of the Body Surface Area (BSA) at Day 1 (Visit 1)

          3. A Physician's Global Assessment of disease severity (PGA) of at least mild on trunk
             and/or limbs at Day 1 (Visit 1)

          4. A modified PASI (m-PASI) score of at least 2 on the trunk and/or limbs at Day 1 (Visit
             1)

        Exclusion:

          1. Topical anti-psoriatic treatment on the trunk and limbs within 2 weeks prior to
             randomisation.

          2. Any previous topical treatment with calcipotriol plus betamethasone gel (Daivobet® gel
             or Xamiol® gel).

          3. Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to
             randomisation.

          4. Ultraviolet B (UVB) therapy within 2 weeks prior to randomisation.

          5. Planned excessive exposure of area(s) to be treated with study medication to either
             natural or artificial sunlight (including tanning booths, sun lamps etc.) during the
             trial.

          6. Subjects who have received treatment with any non-marketed drug substance (i.e. a drug
             which has not yet been made available for clinical use following registration) within
             4 weeks/5 half-lives (whichever is longer) prior to randomisation.

          7. Previously randomised into a clinical trial involving LEO 90100.

          8. Current participation in any other interventional clinical trial.

          9. Previously randomised into this trial.

         10. Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.

         11. Subjects with any of the following conditions present on the treatment area: viral
             (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections,
             parasitic infections, skin manifestations in relation to syphilis or tuberculosis,
             acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ulcers and
             wounds.

         12. Other inflammatory skin disorders (e.g. seborrhoeic dermatitis or contact dermatitis)
             on the treatment area that may confound the evaluation of psoriasis.

         13. Known or suspected disorders of calcium metabolism associated with hypercalcaemia.

         14. Known or suspected severe renal insufficiency or severe hepatic disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Papp, MD phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>K. Papp Clinical Research INC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>K.Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1CR</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <results_first_submitted>August 1, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2016</results_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>219 subjects from Canada (8 sites) and Germany (7 sites) were enrolled into the trial. First Subject First Visit:10-Feb-2015 and Last Subject Last Visit: 03-Aug-2015 (last visit, including follow-up). 6 enrolled subjects were not randomised.</recruitment_details>
      <pre_assignment_details>Screening assessments were performed at the Screening Visit which could occur up to 28 days prior to Baseline (Day 1; Visit 1). A washout period of up to 4 weeks was to be completed if the subject was treated or had recently been treated with anti-psoriatic treatments or other relevant medication, as defined by the exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Foam - Gel</title>
          <description>Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
LEO 90100 Aerosol Foam: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
Daivobet® gel: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.</description>
        </group>
        <group group_id="P2">
          <title>Gel - Foam</title>
          <description>Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
LEO 90100 Aerosol Foam: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
Daivobet® gel: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (Day 1 - Day 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (Day 8 - Day 14)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject in the foam-gel group discontinued from the trial prior to the Week 1 visit and did not complete any on-treatment questionnaires. This subject was excluded from the full analysis set which hence comprised 212 subjects: 108 subjects in the foam-gel group and 104 subjects in the gel-foam group.</population>
      <group_list>
        <group group_id="B1">
          <title>Foam - Gel</title>
          <description>Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel</description>
        </group>
        <group group_id="B2">
          <title>Gel - Foam</title>
          <description>Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="14.0"/>
                    <measurement group_id="B2" value="51.6" spread="14.2"/>
                    <measurement group_id="B3" value="51.9" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Treatment Preference by Subject's Preference Assessment (SPA) at Week 2 and Association With Baseline Characteristics</title>
        <description>The SPA questionnaire was completed at Week 2 and consisted of 2 parts:
(i) the subject indicated if they preferred LEO 90100 foam or Daivobet® gel based on their experience using these products for 1 week each during the 2-weeks treatment period; (ii) the subject indicated how much each of the 22 items under the application, formulation, and container domains contributed to their overall decision of which product they preferred. This part of the SPA tool used a 4-point scale ranging from ‘very important factor’ to ‘not at all important factor’.
The statistical significance of each of the following 7 baseline characteristics (gender, age, disease severity, distribution, plaque size, skin thickness, onset) was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Results of multiple regression analyses are provided in the Clinical Study Report which can be found on the LEO Pharma website.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Randomised Subjects</title>
            <description>All randomised subjects (foam – gel and gel – foam)</description>
          </group>
          <group group_id="O2">
            <title>Foam - Gel</title>
            <description>Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel</description>
          </group>
          <group group_id="O3">
            <title>Gel - Foam</title>
            <description>Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Treatment Preference by Subject's Preference Assessment (SPA) at Week 2 and Association With Baseline Characteristics</title>
          <description>The SPA questionnaire was completed at Week 2 and consisted of 2 parts:
(i) the subject indicated if they preferred LEO 90100 foam or Daivobet® gel based on their experience using these products for 1 week each during the 2-weeks treatment period; (ii) the subject indicated how much each of the 22 items under the application, formulation, and container domains contributed to their overall decision of which product they preferred. This part of the SPA tool used a 4-point scale ranging from ‘very important factor’ to ‘not at all important factor’.
The statistical significance of each of the following 7 baseline characteristics (gender, age, disease severity, distribution, plaque size, skin thickness, onset) was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Results of multiple regression analyses are provided in the Clinical Study Report which can be found on the LEO Pharma website.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall, I preferred the aerosol foam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5"/>
                    <measurement group_id="O2" value="52.9"/>
                    <measurement group_id="O3" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall, I preferred the gel in a bottle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical significance of each of the 7 baseline characteristics was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Baseline factor: gender (male, female).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <p_value_desc>Treatment sequence effect: p=0.28; gender effect: p=0.20; threshold for statistical significance: p&lt;0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>2-factor logistic regression model with treatment sequence and gender as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical significance of each of the 7 baseline characteristics was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Baseline factor: age (18-39 years, 40-59 years, ≥60 years).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.001</p_value>
            <p_value_desc>Treatment sequence effect: p=0.34; age effect: p=0.001; threshold for statistical significance: p&lt;0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>2-factor logistic regression with age and treatment sequence as factors</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical significance of each of the 7 baseline characteristics was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Baseline factor: Baseline disease severity (mild, moderate, severe).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>Treatment sequence effect: p=0.34; baseline disease severity effect: p=0.29; threshold for statistical significance: p&lt;0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>2-factor logistic regression model with treatment sequence and baseline disease severity as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical significance of each of the 7 baseline characteristics was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Baseline factor: distribution phenotype (localised, widespread).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <p_value_desc>Treatment sequence effect: p=0.33; distribution phenotype (localised, widespread) effect: p=0.55; threshold for statistical significance: p&lt;0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>2-factor logistic regression model with treatment sequence and distribution phenotype (localised, widespread) as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical significance of each of the 7 baseline characteristics was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Baseline factor: plaque size (≤3 mm diameter, &gt;3 mm diameter).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <p_value_desc>Treatment sequence effect: p=0.32; plaque size (≤3 mm diameter, &gt;3 mm diameter): p=0.25; threshold for statistical significance: p&lt;0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>2-factor logistic regression model with treatment sequence and plaque size as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical significance of each of the 7 baseline characteristics was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Baseline factor: skin thickness phenotype (≤0.75 mm, &gt;0.75 mm).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>Treatment sequence effect: p=0.34; skin thickness phenotype (≤0.75 mm, &gt;0.75 mm) effect: p=0.41; threshold for statistical significance: p&lt;0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>2-factor logistic regression model with treatment sequence and skin thickness phenotype as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical significance of each of the 7 baseline characteristics was tested in a 2-factor logistic regression model with treatment sequence and each baseline characteristic as factors.
Baseline factor: onset phenotype (≤40 years of age, &gt;40 years of age).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <p_value_desc>Treatment sequence effect: p=0.30; onset phenotype (≤40 years of age, &gt;40 years of age) effect: p=0.20; threshold for statistical significance: p&lt;0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>2-factor logistic regression model with treatment sequence and onset phenotype (≤40 years of age, &gt;40 years of age) as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Within Subject Difference in Response to Topical Product Usability Questionnaire (TPUQ) Items Between Trial Treatments</title>
        <description>Each response category (item 1 to 25) was assigned a numeric score (-2=strongly disagree, -1=slightly disagree, 0=neither agree nor disagree, 1=slightly agree, 2=strongly agree). For item 26, the assigned score were from -2=very dissatisfied to 2=very satisfied.
Summary scores were calculated by summing numeric scores for items under each domain, i.e., application (items 1-9; score range -18 to +18), formulation (items 10-18; score range -18 to +18), container (items 19-22; score range -8 to +8), and satisfaction (items 23-25; score range -6 to +6). Positive scores indicate agreement with domains’ items.
A total TPUQ summary score (item 1-25; score range -50 to +50) was also calculated. The summary scores were analysed in the same way as the individual questions. The higher score signifies higher preference in that domain.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Areosol Foam</title>
            <description>Subject assessments of LEO 90100 aerosol foam. This column shows LEO 90100 foam assessments from the foam-gel group as well as the gel-foam group.</description>
          </group>
          <group group_id="O2">
            <title>Daivobet® Gel</title>
            <description>Subject assessments of Daivobet® gel. This column shows Daivobet® gel assessments from the foam-gel group as well as the gel-foam group.</description>
          </group>
        </group_list>
        <measure>
          <title>Within Subject Difference in Response to Topical Product Usability Questionnaire (TPUQ) Items Between Trial Treatments</title>
          <description>Each response category (item 1 to 25) was assigned a numeric score (-2=strongly disagree, -1=slightly disagree, 0=neither agree nor disagree, 1=slightly agree, 2=strongly agree). For item 26, the assigned score were from -2=very dissatisfied to 2=very satisfied.
Summary scores were calculated by summing numeric scores for items under each domain, i.e., application (items 1-9; score range -18 to +18), formulation (items 10-18; score range -18 to +18), container (items 19-22; score range -8 to +8), and satisfaction (items 23-25; score range -6 to +6). Positive scores indicate agreement with domains’ items.
A total TPUQ summary score (item 1-25; score range -50 to +50) was also calculated. The summary scores were analysed in the same way as the individual questions. The higher score signifies higher preference in that domain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1. Ease of application</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Ease of application on psoriasis lesions only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.3"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Ease of spreading</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.8"/>
                    <measurement group_id="O2" value="1.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4. Lack of mess when applying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.2"/>
                    <measurement group_id="O2" value="1.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5. Good for use on smaller areas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.2"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6. Good for use on larger areas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.9"/>
                    <measurement group_id="O2" value="1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7. Quick to apply</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.8"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8. Total time spent acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.7"/>
                    <measurement group_id="O2" value="1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9. Easily incorporated into daily routine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.9"/>
                    <measurement group_id="O2" value="1.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total application score (summary score item 1-9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="6.9"/>
                    <measurement group_id="O2" value="12.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10. Quickly absorbed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.3"/>
                    <measurement group_id="O2" value="0.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11. Dried quickly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.3"/>
                    <measurement group_id="O2" value="0.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12. Gave an immediate feeling of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.0"/>
                    <measurement group_id="O2" value="0.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13. Felt soothing to my skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.0"/>
                    <measurement group_id="O2" value="1.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14. Appealing to touch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.1"/>
                    <measurement group_id="O2" value="0.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15. Felt moisturising to my skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.0"/>
                    <measurement group_id="O2" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16. Not greasy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.5"/>
                    <measurement group_id="O2" value="0.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17. Odourless</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="1.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18. Lack of staining of clothes/bed linen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.3"/>
                    <measurement group_id="O2" value="1.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total formulation score (summary score item 10-18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="7.2"/>
                    <measurement group_id="O2" value="8.0" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19. Easy to get medication out of container</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.2"/>
                    <measurement group_id="O2" value="1.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20. Easy to use container</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.2"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21. Easy to keep container clean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.1"/>
                    <measurement group_id="O2" value="1.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>22. Accurately dispense wanted amount</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total container score (summary score item 19-22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="3.8"/>
                    <measurement group_id="O2" value="5.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23. Confidence in using the product</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.1"/>
                    <measurement group_id="O2" value="1.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24. Would regularly use the product</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.2"/>
                    <measurement group_id="O2" value="1.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25. Would recommend the product</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.1"/>
                    <measurement group_id="O2" value="1.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total satisfaction score(summary score item 23-25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.2"/>
                    <measurement group_id="O2" value="3.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total TPUQ score (summary score item 1-25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="17.8"/>
                    <measurement group_id="O2" value="29.9" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26. Overall satisfaction score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.0"/>
                    <measurement group_id="O2" value="1.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subjects in the analysis are 212 - full analysis set. All subjects received both study treatments. Total TPUQ score (summary score item 1-25) superiority comparison gel versus foam.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>The total TPUQ score for the gel and the foam (mean score 29.9 vs. mean score 26.8; p=0.007).
Threshold for statistical significance: p&lt;0.05.</p_value_desc>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Wilcoxon rank sum test comparing the period difference (within subject difference between study treatments) between both treatment sequences.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Within Subject Difference in Response to TPUQ Between the Last Topical Anti-psoriatic Treatment and Each of the 2 Trial Treatments</title>
        <description>The TPUQ tool was used to evaluate the subject’s latest topical treatment at Baseline (used within 3 months prior to baseline). TPUQ assessments of trial treatments at Week 1 and Week 2.
Each response category (item 1 to 25) was assigned a numeric score from-2=strongly disagree to 2=strongly agree. For item 26 the assigned scores were from -2=very dissatisfied to 2=very satisfied.
Summary scores were calculated by summing numeric scores for items under each domain, i.e., application (items 1-9; score range -18 to +18), formulation (items 10-18; score range -18 to +18), container (items 19-22; score range -8 to +8), and satisfaction (items 23-25; score range -6 to +6).
For each subject and each item, the latest topical treatment score was compared with each study treatment by calculating the difference between the scores, i.e., by subtracting the latest topical treatment score from each study medication score. The higher score signifies higher preference in that domain.</description>
        <time_frame>Baseline to Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latest Topical Treatment</title>
            <description>Subjects who had used topical treatment to treat their psoriasis within 3 months prior to baseline. Assessments of last topical treatment (TPUQ tool) at baseline.</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Aerosol Foam</title>
            <description>Subjects who had used topical treatment to treat their psoriasis within 3 months prior to Baseline.
Subject assessments of LEO 90100 aerosol foam. This column shows LEO 90100 aerosol foam assessments from the foam-gel group as well as the gel-foam group.</description>
          </group>
          <group group_id="O3">
            <title>Daivobet® Gel</title>
            <description>Subjects who had used topical treatment to treat their psoriasis within 3 months prior to baseline.
Subject assessments of Daivobet® gel. This column shows Daivobet® gel assessments from the foam-gel group as well as the gel-foam group.</description>
          </group>
        </group_list>
        <measure>
          <title>Within Subject Difference in Response to TPUQ Between the Last Topical Anti-psoriatic Treatment and Each of the 2 Trial Treatments</title>
          <description>The TPUQ tool was used to evaluate the subject’s latest topical treatment at Baseline (used within 3 months prior to baseline). TPUQ assessments of trial treatments at Week 1 and Week 2.
Each response category (item 1 to 25) was assigned a numeric score from-2=strongly disagree to 2=strongly agree. For item 26 the assigned scores were from -2=very dissatisfied to 2=very satisfied.
Summary scores were calculated by summing numeric scores for items under each domain, i.e., application (items 1-9; score range -18 to +18), formulation (items 10-18; score range -18 to +18), container (items 19-22; score range -8 to +8), and satisfaction (items 23-25; score range -6 to +6).
For each subject and each item, the latest topical treatment score was compared with each study treatment by calculating the difference between the scores, i.e., by subtracting the latest topical treatment score from each study medication score. The higher score signifies higher preference in that domain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total application score (sum score items 1-9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="6.7"/>
                    <measurement group_id="O2" value="11.5" spread="6.7"/>
                    <measurement group_id="O3" value="12.5" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total formulation score (sum score items 10-18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="7.5"/>
                    <measurement group_id="O2" value="8.3" spread="7.2"/>
                    <measurement group_id="O3" value="7.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total container score (sum score items 19-22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.7"/>
                    <measurement group_id="O2" value="4.6" spread="3.4"/>
                    <measurement group_id="O3" value="5.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total satisfaction score (sum score items 23-25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.0"/>
                    <measurement group_id="O2" value="4.0" spread="3.0"/>
                    <measurement group_id="O3" value="3.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total TPUQ score (items 1-25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="16.9"/>
                    <measurement group_id="O2" value="28.4" spread="17.1"/>
                    <measurement group_id="O3" value="29.0" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26. Overall satisfaction score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.1"/>
                    <measurement group_id="O2" value="1.2" spread="1.0"/>
                    <measurement group_id="O3" value="1.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subjects in the analysis are 118. All subjects received both study treatments. Statistical analysis for total TPUQ score (summary score item 1-25): superiority comparison foam versus latest topical treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Signed Rank Test</method>
            <method_desc>Wilcoxon signed rank test comparing within subject difference to latest topical treatment</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Subjects in the analysis are 118. All subjects received both study treatments. Statistical analysis for total TPUQ score (summary score item 1-25): superiority comparison gel versus latest topical treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Signed Rank Test</method>
            <method_desc>Wilcoxon signed rank test comparing within subject difference to latest topical treatment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responses to Comparison to Last Topical Treatment Questionnaire (CLTT) for Each of the Two Trial Treatments (Foam or Gel)</title>
        <description>Subjects in both arms (foam-gel; gel-foam) indicated whether they preferred latest topical treatment, LEO 90100 aerosol foam, Daivobet® gel, or did not have any preference.
The subjects compared the trial treatment used the previous week with the latest topical treatment (used within 3 months prior to baseline; CLTT analysis set). Each item was scored with either ‘prefer latest treatment’, ‘no preference’, or ‘prefer trial medication (foam or gel)’. A subject could prefer both study treatments over the latest topical treatment. The percentage is given for the number of subjects preferring foam and number of subjects preferring gel.</description>
        <time_frame>At Week 1 and Week 2</time_frame>
        <population>CLTT analysis set was defined by including all randomised subjects who had used topical anti-psoriatic medication on the treatment area (trunk and/or limbs) within 3 months prior to Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects Foam</title>
            <description>Subject assessments of LEO 90100 aerosol foam compared to latest topical treatment (CLTT analysis set).</description>
          </group>
          <group group_id="O2">
            <title>All Subjects Gel</title>
            <description>Subject assessments of Daivobet® gel compared to latest topical treatment (CLTT analysis set).</description>
          </group>
        </group_list>
        <measure>
          <title>Responses to Comparison to Last Topical Treatment Questionnaire (CLTT) for Each of the Two Trial Treatments (Foam or Gel)</title>
          <description>Subjects in both arms (foam-gel; gel-foam) indicated whether they preferred latest topical treatment, LEO 90100 aerosol foam, Daivobet® gel, or did not have any preference.
The subjects compared the trial treatment used the previous week with the latest topical treatment (used within 3 months prior to baseline; CLTT analysis set). Each item was scored with either ‘prefer latest treatment’, ‘no preference’, or ‘prefer trial medication (foam or gel)’. A subject could prefer both study treatments over the latest topical treatment. The percentage is given for the number of subjects preferring foam and number of subjects preferring gel.</description>
          <population>CLTT analysis set was defined by including all randomised subjects who had used topical anti-psoriatic medication on the treatment area (trunk and/or limbs) within 3 months prior to Baseline.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Within Subject Difference in Response to Vehicle Preference Measure (VPM) Items Between Trial Treatments</title>
        <description>The VPM questionnaire was analysed the same way as the TPUQ. Numeric scores were calculated by assigning the following values to each response category: -3 = Extremely unappealing, -2 = Moderately unappealing, -1 = Slightly unappealing, 0 = Neutral, 1 = Slightly appealing, 2 = Moderately appealing, 3 = Extremely appealing. A summary score was defined as the sum of all questions and could range from -21 to 21.</description>
        <time_frame>At Week 1 and Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Areosol Foam</title>
            <description>Subject assessments of LEO 90100 aerosol foam. This column shows LEO 90100 foam assessments from the foam-gel group as well as the gel-foam group.</description>
          </group>
          <group group_id="O2">
            <title>Daivobet® Gel</title>
            <description>Subject assessments of Daivobet® gel. This column shows Daivobet® gel assessments from the foam-gel group as well as the gel-foam group.</description>
          </group>
        </group_list>
        <measure>
          <title>Within Subject Difference in Response to Vehicle Preference Measure (VPM) Items Between Trial Treatments</title>
          <description>The VPM questionnaire was analysed the same way as the TPUQ. Numeric scores were calculated by assigning the following values to each response category: -3 = Extremely unappealing, -2 = Moderately unappealing, -1 = Slightly unappealing, 0 = Neutral, 1 = Slightly appealing, 2 = Moderately appealing, 3 = Extremely appealing. A summary score was defined as the sum of all questions and could range from -21 to 21.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ease of application</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.7"/>
                    <measurement group_id="O2" value="1.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time it takes to apply</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.4"/>
                    <measurement group_id="O2" value="2.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How well it is absorbed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.6"/>
                    <measurement group_id="O2" value="1.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How it feels to touch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.6"/>
                    <measurement group_id="O2" value="1.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How it smells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.5"/>
                    <measurement group_id="O2" value="1.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How it feels on the skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.5"/>
                    <measurement group_id="O2" value="1.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How much it stains</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.5"/>
                    <measurement group_id="O2" value="1.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total VPM score (summary score)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="7.8"/>
                    <measurement group_id="O2" value="12.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reasons for Overall Preference as Assessed by Subject's Preference Assessment (SPA) at Week 2</title>
        <description>Comparison of contribution of each product attribute in the stated preference between trial treatments (foam and gel)</description>
        <time_frame>Baseline to Week 2</time_frame>
        <population>In total 103 preferred foam and 105 preferred gel. 4 subjects ...</population>
        <group_list>
          <group group_id="O1">
            <title>Prefer Foam - Very Important Factor</title>
            <description>Subjects who prefer foam</description>
          </group>
          <group group_id="O2">
            <title>Prefer Foam - Fairly Important Factor</title>
            <description>Subjects who prefer foam</description>
          </group>
          <group group_id="O3">
            <title>Prefer Foam - Not Very Important Factor</title>
            <description>Subjects who prefer foam</description>
          </group>
          <group group_id="O4">
            <title>Prefer Foam - Not at All Important Factor</title>
            <description>Subjects who prefer foam</description>
          </group>
          <group group_id="O5">
            <title>Prefer Gel - Very Important Factor</title>
            <description>Subjects who prefer gel</description>
          </group>
          <group group_id="O6">
            <title>Prefer Gel - Fairly Important Factor</title>
            <description>Subjects who prefer gel</description>
          </group>
          <group group_id="O7">
            <title>Prefer Gel - Not Very Important Factor</title>
            <description>Subjects who prefer gel</description>
          </group>
          <group group_id="O8">
            <title>Prefer Gel - Not at All Important Factor</title>
            <description>Subjects who prefer gel</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Overall Preference as Assessed by Subject's Preference Assessment (SPA) at Week 2</title>
          <description>Comparison of contribution of each product attribute in the stated preference between trial treatments (foam and gel)</description>
          <population>In total 103 preferred foam and 105 preferred gel. 4 subjects ...</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="105"/>
                <count group_id="O7" value="105"/>
                <count group_id="O8" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The medication was easy to apply</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5"/>
                    <measurement group_id="O2" value="30.1"/>
                    <measurement group_id="O3" value="12.6"/>
                    <measurement group_id="O4" value="5.8"/>
                    <measurement group_id="O5" value="54.3"/>
                    <measurement group_id="O6" value="37.1"/>
                    <measurement group_id="O7" value="4.8"/>
                    <measurement group_id="O8" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy application on psoriasis lesions only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="14.6"/>
                    <measurement group_id="O4" value="5.8"/>
                    <measurement group_id="O5" value="61.0"/>
                    <measurement group_id="O6" value="30.5"/>
                    <measurement group_id="O7" value="4.8"/>
                    <measurement group_id="O8" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy to spread</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0"/>
                    <measurement group_id="O2" value="24.3"/>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="5.8"/>
                    <measurement group_id="O5" value="52.4"/>
                    <measurement group_id="O6" value="41.0"/>
                    <measurement group_id="O7" value="2.9"/>
                    <measurement group_id="O8" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Applying the medication was not messy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="15.5"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="45.7"/>
                    <measurement group_id="O6" value="44.8"/>
                    <measurement group_id="O7" value="4.8"/>
                    <measurement group_id="O8" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall good for smaller areas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="29.9"/>
                    <measurement group_id="O3" value="8.2"/>
                    <measurement group_id="O4" value="8.2"/>
                    <measurement group_id="O5" value="50.5"/>
                    <measurement group_id="O6" value="38.4"/>
                    <measurement group_id="O7" value="7.1"/>
                    <measurement group_id="O8" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall good for larger areas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8"/>
                    <measurement group_id="O2" value="25.8"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="6.7"/>
                    <measurement group_id="O5" value="44.2"/>
                    <measurement group_id="O6" value="44.1"/>
                    <measurement group_id="O7" value="10.5"/>
                    <measurement group_id="O8" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment was quick to apply</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="7.8"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="45.7"/>
                    <measurement group_id="O6" value="45.7"/>
                    <measurement group_id="O7" value="4.8"/>
                    <measurement group_id="O8" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total time spent on treatment acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="11.7"/>
                    <measurement group_id="O4" value="4.9"/>
                    <measurement group_id="O5" value="48.6"/>
                    <measurement group_id="O6" value="41.9"/>
                    <measurement group_id="O7" value="6.7"/>
                    <measurement group_id="O8" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Applying treatment easy in daily routine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="24.3"/>
                    <measurement group_id="O3" value="10.7"/>
                    <measurement group_id="O4" value="3.9"/>
                    <measurement group_id="O5" value="56.2"/>
                    <measurement group_id="O6" value="36.2"/>
                    <measurement group_id="O7" value="3.8"/>
                    <measurement group_id="O8" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment quickly absorbed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5"/>
                    <measurement group_id="O2" value="32.0"/>
                    <measurement group_id="O3" value="11.7"/>
                    <measurement group_id="O4" value="4.9"/>
                    <measurement group_id="O5" value="50.5"/>
                    <measurement group_id="O6" value="39.0"/>
                    <measurement group_id="O7" value="9.5"/>
                    <measurement group_id="O8" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment dried quickly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6"/>
                    <measurement group_id="O2" value="35.0"/>
                    <measurement group_id="O3" value="17.5"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="50.5"/>
                    <measurement group_id="O6" value="39.0"/>
                    <measurement group_id="O7" value="9.5"/>
                    <measurement group_id="O8" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment gave immediate feeling of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="18.4"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="39.0"/>
                    <measurement group_id="O6" value="41.0"/>
                    <measurement group_id="O7" value="17.1"/>
                    <measurement group_id="O8" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The medication felt soothing to my skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5"/>
                    <measurement group_id="O2" value="36.9"/>
                    <measurement group_id="O3" value="8.7"/>
                    <measurement group_id="O4" value="3.9"/>
                    <measurement group_id="O5" value="46.7"/>
                    <measurement group_id="O6" value="39.0"/>
                    <measurement group_id="O7" value="12.4"/>
                    <measurement group_id="O8" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The medication was appealing to touch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="14.6"/>
                    <measurement group_id="O4" value="6.8"/>
                    <measurement group_id="O5" value="34.3"/>
                    <measurement group_id="O6" value="39.0"/>
                    <measurement group_id="O7" value="21.0"/>
                    <measurement group_id="O8" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment felt moisturising to my skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6"/>
                    <measurement group_id="O2" value="38.8"/>
                    <measurement group_id="O3" value="11.7"/>
                    <measurement group_id="O4" value="3.9"/>
                    <measurement group_id="O5" value="41.0"/>
                    <measurement group_id="O6" value="43.8"/>
                    <measurement group_id="O7" value="12.4"/>
                    <measurement group_id="O8" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment not too greasy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="30.1"/>
                    <measurement group_id="O3" value="17.5"/>
                    <measurement group_id="O4" value="3.9"/>
                    <measurement group_id="O5" value="43.8"/>
                    <measurement group_id="O6" value="38.1"/>
                    <measurement group_id="O7" value="15.2"/>
                    <measurement group_id="O8" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment was odourless</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="18.4"/>
                    <measurement group_id="O4" value="8.7"/>
                    <measurement group_id="O5" value="38.1"/>
                    <measurement group_id="O6" value="41.0"/>
                    <measurement group_id="O7" value="16.2"/>
                    <measurement group_id="O8" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of staining of clothes/bed linen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="11.7"/>
                    <measurement group_id="O4" value="3.9"/>
                    <measurement group_id="O5" value="54.3"/>
                    <measurement group_id="O6" value="36.2"/>
                    <measurement group_id="O7" value="7.6"/>
                    <measurement group_id="O8" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Getting treatment out of container</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="32.0"/>
                    <measurement group_id="O3" value="10.7"/>
                    <measurement group_id="O4" value="4.9"/>
                    <measurement group_id="O5" value="52.4"/>
                    <measurement group_id="O6" value="41.0"/>
                    <measurement group_id="O7" value="2.9"/>
                    <measurement group_id="O8" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Container easy to use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="10.7"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="57.1"/>
                    <measurement group_id="O6" value="36.2"/>
                    <measurement group_id="O7" value="4.8"/>
                    <measurement group_id="O8" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of keeping clean container</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7"/>
                    <measurement group_id="O2" value="33.0"/>
                    <measurement group_id="O3" value="16.5"/>
                    <measurement group_id="O4" value="7.8"/>
                    <measurement group_id="O5" value="45.7"/>
                    <measurement group_id="O6" value="38.1"/>
                    <measurement group_id="O7" value="16.2"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dispensing the desired amount</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="8.7"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="59.0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="5.7"/>
                    <measurement group_id="O8" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>21 subjects (9.9%) experienced a total of 21 treatment-emergent AEs. No SAEs, severe AEs or AEs leading to withdrawal were observed. 2 subjects had AEs which were assessed as related to study treatment by the investigator: one subject in the foam-gel group experienced folliculitis, and one subject in the gel-foam group experienced dermatitis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Foam - Gel</title>
          <description>Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
LEO 90100 Aerosol Foam: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
Daivobet® gel: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.</description>
        </group>
        <group group_id="E2">
          <title>Gel - Foam</title>
          <description>Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
LEO 90100 Aerosol Foam: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
Daivobet® gel: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 44945888</phone>
      <email>ctr.disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

